SAB Biotherapeutics Sets Virtual Annual Meeting for July 17
Ticker: SABSW · Form: DEF 14A · Filed: Jun 2, 2025 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | DEF 14A |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Biotechnology, Virtual Meeting, SEC Filing
Related Tickers: SABSW
TL;DR
**SAB Biotherapeutics' virtual annual meeting on July 17th is a routine governance check, but investors should still vote on Class I directors to shape future leadership.**
AI Summary
SAB Biotherapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on June 2, 2025, for its Annual Meeting of Stockholders scheduled for July 17, 2025, at 10:00 AM Eastern Time. The meeting will be held virtually at www.virtualshareholdermeeting.com/SABS2025. The primary business item for the meeting is the election of four Class I directors. The company, operating in the biological products sector, emphasizes the importance of stockholder participation through internet, telephone, or mail proxy voting, regardless of virtual attendance. This filing does not disclose specific revenue or net income figures, nor does it detail key business changes or strategic outlook beyond the standard annual meeting agenda. Risks are implicitly tied to corporate governance and board composition, as the election of directors is the sole stated agenda item. The company's CEO and Chairman, Samuel J. Reich, signed the invitation to stockholders, underscoring leadership's call for engagement.
Why It Matters
This DEF 14A filing signals SAB Biotherapeutics' commitment to corporate governance by scheduling its 2025 Annual Meeting, where stockholders will elect four Class I directors. For investors, this is a crucial opportunity to influence the company's leadership and strategic direction, especially in the competitive biological products sector. Employees and customers will watch board composition for stability and strategic shifts that could impact product development and market positioning. The virtual format at www.virtualshareholdermeeting.com/SABS2025 reflects a modern approach to shareholder engagement, common among biotech firms.
Risk Assessment
Risk Level: low — The risk level is low because this DEF 14A filing is a standard procedural document for an annual meeting, primarily focused on the election of four Class I directors. It does not introduce new financial risks or significant operational changes, but rather outlines a routine corporate governance event for July 17, 2025.
Analyst Insight
Investors should review the accompanying proxy statement for details on the four Class I director nominees and cast their votes by proxy via internet, telephone, or mail before the July 17, 2025 meeting. Active participation in director elections is crucial for influencing SAB Biotherapeutics' long-term strategic direction and oversight.
Key Numbers
- 4 — Number of Class I directors to be elected (Primary item of business at the Annual Meeting)
- 2025-06-02 — Filing date of DEF 14A (Date the proxy statement was filed with the SEC)
- 2025-07-17 — Date of Annual Meeting (When stockholders will vote on directors)
- 10:00 AM ET — Time of Annual Meeting (Scheduled start time for the virtual meeting)
- 001-39871 — SEC File Number (Identifier for SAB Biotherapeutics' SEC filings)
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Registrant filing the DEF 14A
- Samuel J. Reich (person) — Chief Executive Officer and Chairman of the Board
- July 17, 2025 (date) — Date of the Annual Meeting of Stockholders
- 10:00 AM Eastern Time (time) — Scheduled start time of the Annual Meeting
- www.virtualshareholdermeeting.com/SABS2025 (website) — Virtual meeting platform for the Annual Meeting
- United States Securities and Exchange Commission (regulator) — Regulatory body overseeing the filing
- Big Cypress Acquisition Corp. (company) — Former name of SAB Biotherapeutics, Inc.
- November 20, 2020 (date) — Date of name change for the company
- Miami Beach, FL (location) — Business address of SAB Biotherapeutics, Inc.
- 0001833214 (identifier) — Central Index Key (CIK) for SAB Biotherapeutics, Inc.
FAQ
When is SAB Biotherapeutics' 2025 Annual Meeting of Stockholders?
SAB Biotherapeutics, Inc.'s 2025 Annual Meeting of Stockholders is scheduled for Thursday, July 17, 2025, at 10:00 AM Eastern Time.
Where will SAB Biotherapeutics' Annual Meeting be held?
The Annual Meeting for SAB Biotherapeutics, Inc. will be a completely virtual meeting, conducted exclusively on the Internet at www.virtualshareholdermeeting.com/SABS2025. No physical meeting will be held.
What is the main item of business at the SAB Biotherapeutics Annual Meeting?
The primary item of business at the SAB Biotherapeutics Annual Meeting is to elect the four Class I directors listed in the accompanying proxy statement.
Who is the CEO and Chairman of the Board for SAB Biotherapeutics, Inc.?
Samuel J. Reich is the Chief Executive Officer and Chairman of the Board for SAB Biotherapeutics, Inc., and he signed the invitation to stockholders.
How can SAB Biotherapeutics stockholders vote for the Annual Meeting?
SAB Biotherapeutics stockholders can vote by proxy over the Internet, by telephone, or by mail by following the instructions on the proxy card or voting instruction card.
What type of SEC filing is this document for SAB Biotherapeutics?
This document is a Definitive Proxy Statement, identified as a DEF 14A filing, submitted by SAB Biotherapeutics, Inc. to the SEC.
What was the former name of SAB Biotherapeutics, Inc.?
The former conformed name of SAB Biotherapeutics, Inc. was Big Cypress Acquisition Corp., with the name change occurring on November 20, 2020.
What is the fiscal year end for SAB Biotherapeutics, Inc.?
SAB Biotherapeutics, Inc. has a fiscal year end of December 31, as indicated in the filing data.
Is there a filing fee required for this SAB Biotherapeutics DEF 14A?
No fee is required for this SAB Biotherapeutics DEF 14A filing, as indicated by the checked box 'No fee required' in the Payment of Filing Fee section.
What industry is SAB Biotherapeutics, Inc. classified under?
SAB Biotherapeutics, Inc. is classified under the Standard Industrial Classification (SIC) code for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Industry Context
SAB Biotherapeutics, Inc. operates within the biological products sector, a segment of the broader biotechnology industry focused on developing and manufacturing therapeutic proteins and antibodies. This industry is characterized by significant research and development investment, lengthy regulatory approval processes, and intense competition from both established pharmaceutical companies and emerging biotech firms.
Regulatory Implications
As a company in the biological products sector, SAB Biotherapeutics, Inc. is subject to stringent regulatory oversight by bodies such as the Food and Drug Administration (FDA). While this specific filing focuses on corporate governance, any future product development or commercialization would necessitate adherence to complex manufacturing, safety, and efficacy standards, posing ongoing compliance risks.
What Investors Should Do
- Review the proxy statement to understand the qualifications and backgrounds of the director nominees before the July 17, 2025 meeting.
- Vote your shares, either online, by phone, or by mail, to ensure your voice is heard on the election of directors, regardless of whether you attend the virtual meeting.
Key Dates
- 2025-06-02: Filing of Definitive Proxy Statement (DEF 14A) — Provides official notice to stockholders about the upcoming annual meeting and the matters to be voted upon, including director elections.
- 2025-07-17: Annual Meeting of Stockholders — The date on which stockholders will vote on the election of directors and other potential business.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC by a company soliciting proxies from its shareholders for an annual or special meeting. (This is the primary document filed by SAB Biotherapeutics, Inc. detailing the agenda and voting matters for its annual meeting.)
- Class I directors
- Directors who are elected for a specific term, typically one of three classes in a staggered board structure, and whose terms expire at a particular annual meeting. (The election of four Class I directors is the sole stated item of business for the SAB Biotherapeutics, Inc. annual meeting.)
- Virtual Meeting
- A meeting conducted entirely online, allowing participants to attend and interact remotely via the internet. (SAB Biotherapeutics, Inc. is holding its 2025 Annual Meeting of Stockholders virtually, requiring specific instructions for participation.)
Year-Over-Year Comparison
This filing is a standard DEF 14A for an annual meeting and does not contain comparative financial data or operational updates from a previous filing. The primary focus is on the upcoming election of directors, with no information provided on changes in revenue, net income, or strategic shifts compared to prior periods.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 2, 2025 by Samuel J. Reich regarding SAB Biotherapeutics, Inc. (SABSW).